Asian Journal of Pharmaceutical Technology & Innovation
ISSN: 2347-8810

Review Article

Received on: 14-03-2015
Accepted on: 26-03-2015
Published on: 15-04-2015
Corresponding Author:

*** Pramod Singh Khatri,**
Head of Department and Programme Coordinator, Dept. of Clinical Research, Amity Medical School, Amity University, Haryana, India.

*Email Id-
pramodsinghkhatri@gmail.com

Prostate Cancer Stem Cell –Future Outlook

Pramod Singh Khatri*

ABSTRACT

Prostate cancer is presently a typical ailment in men more than 50 years old. Medicinal treatments for prostate cancer are in light of disclosures from the mid-twentieth century, and in the long term are seldom curative. Most medicines are coordinated towards an androgen receptor expressing, highly proliferative target cell, which does undoubtedly structure the greater part of cells in a prostate tumor. Notwithstanding, by conjuring the presence of a cancer stem cell which, in the same way as typical epithelial stem cell in the prostate, does not represent androgen receptor and is generally silent, the observed imperviousness to most therapeutic treatments can be clarified. The phenotype of the prostate cancer stem cell is that of a basal cell and culture derived from cancer, yet not benign tissues, express a variety of prostate cancer related RNAs. Moreover, stem cells filtered on the premise of alpha2beta1 high integrin and CD133 cell surface antigen articulation, from a culture of Gleason 4 (2+2) prostate tumor (P4E6), had the capacity to form numerous intra prostatic tumors in naked mice when joined orthotopically in a matrigel attachment containing human prostatic stroma. The final tumors reexpressed androgen receptor and showed a histology like that of a Gleason 4 cancer.

The presence of prostate cancer stem cells offers a hypothetical clarification for a large portion of the persevering vulnerabilities encompassing the etiology and treatment of the most usually diagnosed tumor in US men. The investigation of cancer stem cells in prostate, is basically reliant on the accessibility of untainted cell population, a circumstance entangled by the heterogeneity of prostate tumors. Be that as it may, choice of cells with a $CD133^+/\alpha2\beta1$ integrin/ $CD44^+$ phenotype improves for a tumor-starting population from human prostate cancer. Among the most squeezing needs is for persisting treatment in subjects who have encountered failure of hormonal medicines. Since the putative cancer stem cell do 'not express androgen receptor, it is liable to be immune from most androgen-based treatments, and an inalienable hereditary instability would empower the tumor to develop the new variations present in hormone-refractory disease. Prostate cancer stem cell have a special gene articulation signature that can likewise be identified with Gleason grade and patient result. The shortage of cancer stem cell in a prostate tumor will presumably confine their handiness in cancer finding and visualization. Be that as it may, the rise of new stem cell therapeutic targets not just will oblige new tests for efficacy (due to their generally silent nature), additionally holds genuine promise of more enduring medicines to enlarge those presently coordinated against the remaining tumor cells, which embody 99.9% of tumor mass, however incomprehensibly have a poor tumor-initiating limitation.

Key-words: prostate cancer, cancer stem cells, prostate cancer stem cells, differentiation, therapy resistance

Cite this article as:
Pramod Singh Khatri, Prostate Cancer Stem Cell –Future Outlook, Asian Journal of Pharmaceutical Technology & Innovation, 03 (11); 2015. www.asianpharmtech.com*

Introduction:-

Prostate cancer has been perceived as a clinical substance since relic, when it was initially portrayed by the antiquated Egyptians, while surgical methodology to uproot the prostate were developed >100 years back[1]. Notwithstanding, the accessibility of an available blood test for prostate-specific antigen (PSA) has revolutionized the determination of prostate cancer over the last three decades. PSA is a kallikrein-related serine protease that is produced in ordinary prostate secretions, however is discharged into the blood as a result of disturbance of typical prostate architecture[2-3].

In the same way as other cancer types, Prostrate Cancer *(Figure 1)* is heterogeneous concerning both histo structures and cell structure. Case in point, albeit most restricted, early-staged PCa are essentially made out of separated glandular structures in which cells are positive for prostate-specific antigen (PSA) and androgen receptor (AR), poorly separated or stem ranges can likewise be recognized where cells are to a great extent negative for PSA and AR articulation. Then again, progressed PCa for the most part comprise of poorly separated, however separated areas can likewise be seen[4]. The heterogeneous interpretation patterns of PSA and AR in PCa cells suggest the presence of distinct cell subpopulations, i.e., $PSA^{+}AR^{+}$, $PSA^{+}AR^{-}$, $PSA^{-}AR^{+}$ and $PSA^{-}AR^{-}$. A latest study investigated the Docetaxel-tolerant phenotype in both untreated human PCa (HPCa) and metastatic specimens, and found that all tumors contained two subpopulation of PCa cells, i.e., cytokeratin (CK) $18^{+}/19^{+}$ and $CK18^{-}/CK19^{-}$ cells[5].

Figure 1:- Prostate Cancer Metastasis



Prostate epithelium and stem cell

Human prostate is an exocrine organ that comprises of basal, luminal and neuroendocrine cell types inserted in a fibro-muscular stroma. The basal cells are moderately stem, not reliant on androgens and thus express low levels of androgen receptors (ARs) [6]. Also, basal cells develop some secretory items, for example, CD44, p63, $p27^{kip}$ and c-Met, cytokeratin 5 (CK 5) and CK 14. Rather than the basal layer of cells, luminal (or secretory) cells are terminally separated and particularly discharge the prostate like prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) into the glandular medulla in light of androgens. Since, survival of these luminal cells rely upon androgens they express ARs on an abnormal level; though, their other particular secretory items are CD57, CK 8 and CK 18. The third kind of cell in the cell organization of the prostate epithelium is the neuroendocrine (NE) cell. The particular function of NE cells have not been found so far. Nonetheless, scientist recommended that they are post-mitotic cells got from luminal secretory cells[7].

NE cells are terminally separated, androgen insensitive and scattered all through the epithelium. Not at all like the luminal cells, NE cells don't express AR or PSA; in any case, they do express NE-specific markers, for example, chromogranin A and synaptophysin. Basal and luminal cells can likewise be recognized by looking at expression profile of different genes; like basal cells do predominantly express CK 5 and CK 14, while luminal cells express CK 8 and CK 18. Morphologically basal cells are small, straightened cells with condensed chromatin and small amount of cytoplasm. Luminal cells rather have expanded cytoplasm and their chromatin seem more opened. At last, the stroma is spotted under the epithelial layer of prostate[8].

Stromal cells are androgen responsive and they do express AR. development, maintenance and separation of epithelial cells are given by these stromal cells.

Molecular mechanism of prostate cancer initiation and progression

Albeit every event has been connected with a conceivable role in cancer initiation or movement, it is obscure whether there is a transient sequence associated with these events, or whether there is a causal relationship among them[9].

NKX3.1 down Regulation

Down regulation of the NKX3.1 home box gene signifies a continuous and discriminating event in prostate tumor initiation, and is liable to include various mechanism. NKX3.1 will be limited inside a 150-Mb minimal deleted area of chromosome 8p21.2 that shows loss-of-heterozygosity (LOH) in up to 85% of high-grade PIN sores and adenocarcinomas[10]. In any case, despite the fact that LOH of 8p21 continuously increases in recurrence with cancer grade, the remaining allele of NKX3.1 stays unmutated. Furthermore, whether 8p21 LOH has happened, there is generous proof that NKX3.1 experiences epigenetic down regulation, maybe through promoter methylation. Albeit prior studies had recommended that NKX3.1 expression will be totally lost in advance cancer, latest investigations utilizing an highly sensitive antibody demonstrate that low levels of NKX3.1 expression can be exhibited in about all prostate cancers and metastases investigated. Accordingly, there seems, by all accounts, to be a determination for reduction, yet not loss, of NKX3.1 expression all through prostate tumor progression[11].

These discoveries are highly suggestive, since Nkx3.1 has been indicated to be a discriminating controller of prostate epithelial differentiation and stem cell work in mouse models. Amid development, Nkx3.1 is expressed in all epithelial cells of the beginning prostate buds from the urogenital sinus, and represent most known marker for the prostate epithelium[12].

Emasculation resistant prostate cancer

Flowing androgens are vital for typical prostate development as well as the onset of prostate cancer through their collaborations with the androgen receptor (AR). The evacuation of testicular androgens by surgical or chemical maiming will lead to relapse of prostate tumors. Notwithstanding, androgen depletion will be normally connected with the recurrence of prostate tumor, as observed by rising PSA levels, and this repetitive malady is termed ''castration resistant.'' Unfortunately, maiming resistant prostate cancer has been basically untreatable, with the best standard chemotherapeutic regimens bringing about a mean increment in survival time of 2 months[13-14]. Accordingly, a second major clinical challenge that could be essentially affected by essential research in prostate cancer science is the illustration of pathways of mutilation resistance, which could lead to the Identification of new therapeutic methodologies.

Recognizing lethargic versus aggressive tumor

These new suggestions were proposed on the grounds that the broad utilization of PSA testing has prompted a limitless increase in the diagnosis of subjects with clinically localized low Gleason grade carcinomas that may not oblige treatment, since their tumors are generally slothful. In specific, subjects with a Gleason pattern of 3 or less never backslide after local treatment, and likely can be overseen conservatively with ''watchful waiting''; in any case, a little division of these tumors will advance quickly and require quick treatment[15] .

Therefore, a noteworthy clinical test is postured by the current inability to promptly recognize sluggish from aggressive tumors in prostate tumor patients who present with low Gleason grade tumors after biopsy. The nonappearance of this prognostic data has prompted a noteworthy ""overtreatment"" of subjects who would require just conservative management. Subsequently, the effect of treatment on prostate cancer survival is small, no doubt in light of the fact that over diagnosis and overtreatment weakens the profits of treatment for the individuals who oblige intervention[16]. This prognostic test could be tended for better comprehension of the molecular basis of cancer initiation, which ought to eventually prompt the identification of biomarkers that recognize sluggish and aggressive forms of prostate cancer. At present, nonetheless, available molecular biomarkers don't give more prominent prognostic significance than Gleason grade determination[17].

Translational applications

Recently, principal areas of translational research on prostate tumor have concentrated on:-

- Comprehension the dietary/way of life/environmental variables that impact prostate carcinogenesis, and recognizing methodologies to delay its onset or progression;
- Distinguishing biomarkers that recognize indolent versus aggressive forms of the ailment, and the application of such biomarkers for subject stratification; and
- Developing new therapeutic methodologies for the treatment of maiming resistant prostate cancer, for avoidance of bone metastases. For example, utilization of novel therapeutic methodology that may be ensuring is the use of immunotherapy, as demonstrated by the latest FDA approval of a remedial vaccine (Provenge) for advanced prostate cancer patients[18-20].

Prostate cancer stem cells

Inception of PCSCs

The inception of PCSCs keeps on staying as a disputable issue. Diverse cells in origin may create clinically important subtypes with distinctive prognosis and result. There are two possible cell origin assets in PC: the basal and luminal cell-of-origin[21].

Basal cell of inception

Much stronger investigation originated from various labs that utilized diverse Prostate Cancer models to bolster the perspective that basal stem cell give the cell of origin for Prostate Cancer. At the point when $CD49f^{hi}Trop2^{hi}$ cells were chosen from the basal portion, transfected with Akt/Erg vectors and transplanted to instigate initiation of prostatic intraepithelial neoplasia; these basal cells derived from human prostate tissue initiated Prostate Cancer in immune deficient mice. It was additionally reported that $Lin^{-}Sca\text{-}1^{+}CD49f^{hi}$ cells disengaged from the basal portion of murine prostate delivered luminal-like sickness characteristics of human Prostate Cancer after transplantation. Recently scientist reported that selected cells with basal phenotypes are tumor initiating and basal Stem Cells are the source of a luminal descendants[22]. Also, a little population of $TRA\text{-}1\text{-}60^{+}$ $CD151^{+}$ $CD166^{+}$ tumor initiating cells (TICs) detached from human prostate xenograft tumors showed stem-like cell characteristics and summarized the cell pecking order of the original tumor in serial xenotransplantation tests. In addition, these cells expressed basal cell markers and demonstrated expanded nuclear factor κB (NF-κβ) flagging.

Luminal cell of inception

Luminal cells are accepted to be the cells of origin for human Prostate Cancer, in light of the fact that the ailment is described by AR^{+} luminal cell expansion. That is the reason pathologists diagnose Prostate Cancer in view of the absence of basal cell markers[23]. It is known, that uncommon luminal cells which express the homeobox gene Nkx3.1 without testicular androgens (castration resistant Nkx3.1-expressing cells, CARNs) are bi-potential with restoration toward oneself ability in vivo. Single-cell transplantation of CARNs can reconstitute prostate pipes in renal grafts. Moreover, targeted deletion of PTEN in CARNs brings about fast development of carcinoma after androgen mediated recovery. Scientist has indicated that genetic alterations are first seen in a subset of luminal cells communicating the progenitor markers TROP2 and SCA-1, inferring that the luminal cells are the cell of origin in this model. Since Prostate Cancer is an extremely heterogeneous disease it is conceivable that diverse Prostate Cancers are derived from distinctive originating cell types.

Classification and markers of PCSCs

Each stem cell does not express the characterized markers that are utilized to segregate Stem Cells from different cancerous or typical tissues. In spite of the fact that the CD133, CD44, SCA1 and THY1 cell surface markers are generally used to enrich CSCs; they are likewise expressed in typical stem cell and also in numerous non-stem cells in different tumors and tissues. In the long run, the larger part of cells expressing these markers are not Stem Cells. Aside from that, a marker that is discovered to be useful in recognizing a Stem Cell from one tissue may not be valuable for distinguishing the Stem Cell in an alternate tissue[24]. An alternate practical method for recognizing Stem Cells, other than hunting down particular cell surface markers, is by label retention assay .This DNA labeling assay relies upon the label retaining attributes of rarely dividing Stem Cells. At last, CSCs can be isolated by the recognition of a "side population (SP)" of cells that effectively transport lipophilic colors out of the cells by medication transporting proteins. Scientist initially observed that a little populace of bone marrow-inferred cells that were brooded with the lipophilic dye (Hoechst 33342) failed to amass a calculable measure of this dye. This subpopulation was distinguished by double wavelength flow cytometry investigation as the $Hoechst^{low}SP$. Astoundingly, the SP was exceptionally enhanced for hematopoietic stem cells. In this manner, the SP strategy was broadly utilized to enhance stem like cells from solid cancer. This technique was likewise utilized for Prostate Cancer cells and the SP of cells resultant from this

primary prostate tumors was ~1%. Since the highest level to affirm CSCs is in vivo tumor development, analyzed and sorted SP cells were immunized into immune deficient mice and tried for tumor producing capacity. By this, it was figured out that cell surface markers consolidated with SP analysis are more accurate way in distinguishing the real Stem Cell population[25].

Modifications in flagging pathways of PCSCs

Modifications in the flagging pathways are likely one of the reasons why cancer stem cell increase a tumorigenic potential. Consequently, revealing the flagging pathways' expressional regulations may give potential therapeutic targets. The WNT, JAK/STAT, NF-κβ, NOTCH, and PI3K/AKT/mTOR flagging pathways were discovered to be the controllers of Cancer Stem Cell science in prostate tissue and subsequently are candidate targets[26]. The thought of restraining flagging that affects multiplication and survival could mean a powerful treatment for Prostate Cancer.

Proteins acting in the WNT flagging pathway are over-expressed in PCSCs. Henceforth, tumorigenesis is advanced and prostaspheres which have renewal toward oneself exhibit proliferation, separation, and heterogeneous expression of stem cell related markers, for example, CD44, ABCG2 and CD133. At the point when WNT inhibitors are connected the extent of prostaspheres and their self-renewal capacity can be diminished; also, the CD133 and CD44 expressions are down regulated[27]. WNT activity likewise controls the self-renewal capacity of Prostate Cancer cells that have stem cell like peculiarities and restraint of WNT flagging possibly decreases the self-renewal capacity of PCSCs with a fortunate therapeutic result.

The JAK/STAT flagging pathway is by all accounts essential in PCSC biology. Then, when PCSCs expressing aldehyde dehydrogenase ($ALDH^+$), which is included in the development of bone metastasis, were dealt with by means of a galiellactone- a particular STAT3 flagging inhibitor-; apoptosis of cancerous cells could be instigated. Furthermore, in vivo targeting of STAT3 in a medication treated DU145 xenograft gave additionally craved results. Consequently, focusing of JAK/STAT flagging pathway may be a promising remedial bringing about ALDH1A1 expressional down-regulation in PSCSs. The significance of the NF-κβ flagging pathway came up after the finding of improved functional signaling in filtered guileless stem-like human prostatic TICs. At the point when cells were treated with small molecular inhibitors that focused on the NF-κB signaling pathway secondary sphere formation in vitro and tumor-initiation in vivo could be restrained.

Cell destiny specification, initiation of separation, and Stem Cell support is managed by the NOTCH flagging pathway in numerous tissues. The overexpression of different proteins that function in the NOTCH flagging cascade has been found in various distinctive tumors including Prostate Cancer[28]. Case in point JAGGED-1, a NOTCH receptor ligand, has been discovered to be essentially more expressed in metastatic Prostate Cancer when contrasted with localized Prostate Cancer. This up-regulation additionally connected with clinical gimmicks like repeat, progression and metastasis of Prostate Cancer. At the point when Jagged-1 expression was down-regulated with small interfering RNAs (siRNAs) cell cancer was repressed and cell cycle arrest accomplished in the S period of cell division.

The PI3K/AKT/mTOR flagging pathway member PTEN was initially distinguished as a candidate tumor suppressor gene that was often transformed in brain, breast, and prostate tumors. Introduction of PTEN into cancer cells that need PTEN function down-regulation cell movement and survival, and impelled cell cycle arrest and apoptosis. PTEN is the most transformed gene in metastatic Prostate Cancer that is progressed and has an aggressive tumor phenotype; and has been connected with cancer progression in 30–60% of Prostate Cancer cases[29]. An affiliation between androgen-independent tumor cancer and PTEN transformations has likewise been discovered. Various mouse models for Prostate Cancer proposed that PTEN may assume a role in the initiation or early progression of this ailment. PTEN heterozygous mice are liable to develop epithelial dysplasia and hyperplasia resembling high-grade PIN and adenocarcinoma.

Possible role of PCSCs in metastasis

Prostate Cancer is the second leading reason for cancer demise in male; yet, due to the advancement made in the analysis and treatment of essential Prostate Cancer, mortality in 70 - 80% of the patients is progressively linked to its metastatic disease[30]. The bone marrow is the most common site for metastasis in Prostate Cancer; and stem cell, other than their role in tumorigenicity, are exceptionally transient cells that are involved in bone metastasis development.

CSCs contain a subpopulation of cells that are solely capable for scattering and in this manner giving the substrate to tumor metastasis; e.g. $CD44^+$ Prostate Cancer cells are more tumorigenic and metastatic than the comparing $CD44^-$ cells. Stromal cell derived factor and its C-X-C chemokine receptor type 4 (CXCR4) form a basic regulatory pivot for Stem Cell movement, engraftment and homing, furthermore work in the metastasis of breast and prostate cancer. Utilizing a mouse/human relative

translational genomics approach an 11-gene signature that reliably shows a stem cell–like articulation design in metastatic lesions of prostate carcinomas could be recuperated from different distant target organs[31].

Then again, a few occurrences don't bolster the CSC contribution in metastasis. For instance, $CD44^{+}CD24^{-}$ and $CD44^{+}CD24^{+}$ breast CSCs have same metastatic potential. At this point, in an orthotropic pancreatic tumor model $CD133^{+}$ cells were not metastatic, though $CD133^{+}CXCR4^{+}$ cells demonstrated solid metastasis[32]. Additionally, $CD133^{-}$ colon cancer cells were more aggressive and metastatic than their $CD133^{+}$ counterparts. In conclusion, metastasis and tumor initiation may be handled by distinct cancer cell population, presumably by metastatic CSCs.

Tumor microenvironment encourages cancer metastasis by a few mechanism. At the point when human Prostate Cancer cells were infused into the dorsal prostate of a naked mouse more metastasis was generated, than when cells were infused subcutaneous. Later, it was demonstrated that dorsal prostate-implanted human Prostate Cancer cells over-express numerous CSC genes including osteoponin, CXCR4, CD133, ABCG2, CD44 and CD24. Some of these genes obviously have functional roles in Prostate Cancer metastasis. In any case, the exact molecular mechanism that account for the microenvironment regulated Prostate Cancer cell metastasis are still not known[33].

New therapeutic methodologies in targeting PCSCs

Regardless of advancement in the remedial methodologies that fundamentally expanded the survival rate of Prostate Cancer patients, most prostate aggressive tumors get to be impervious to as of now utilized treatment protocols[34]. Prostate Cancer that at first responded well to a standard chemotherapy frequently recur with particular tumor cell subpopulations and get resistant to the first chemotherapeutic agent as well as to different therapeutics. Consequently, for most patients with relapse of castration resistant metastatic Prostate Cancer as of now no remedial treatment exists. It has been recommended that AR expression in Prostate Cancer is modulated by CSCs and the CSC model may be responsible for the level of sensitivity to anti androgen treatment[35].

The majority of investigation to date have concentrated on the identification of characteristics that conceivably could describe CSCs[36-40]. Notwithstanding, more inquiries have been raised on the issue which of these attributes would be better suited as target and now research has appeared to shift towards identifying the way these CSCs behave that make them not the same as mass tumor cells. Two essential peculiarities of AML that permit for revelation of new therapeutic agents were $CD34^{+}/CD38^{-}$ and $CD33^{+}$. Anti CD33 antibodies have turned into a critical aspect of CSCs treatment (figure 2). A medication called Gemtuzumab, ozogamacin or Mylotarg, approved by the FDA in 2000, combines the cytotoxic antibiotic calicheamicin with the monoclonal anti CD33 antibody[41].

Latest studies have uncovered that the blockade of these tumorigenic flagging cascades could be useful as adjuvant treatment in the early periods of Prostate Cancer for diminishing the risk of relapse and in addition in the late stages for enhancing the efficacy of current androgen treatment, radiotherapy, and systemic chemotherapy and patient survival rates[42]. Inhibition of the epidermal cancer factor (EGFR) pathway by anti EGFR pathway or EGFR tyrosine kinase inhibitor causes a cell cycle arrest, prompts apoptosis in metastatic Prostate Cancer cells when connected in vitro or in vivo. Blockade of the SHH flagging pathway, which is imperative in stem cell self-renewal, by cyclopamine prompts long term Prostate Cancer relapse without recurrence, unequivocally proposing an association between this pathway and Prostate Cell Stem Cells. Salinomycin, a structurally related compound to monensin, was recently recognized as an intense PCSC inhibitor. It inhibited the cancer of Prostate Cancers, yet did not influence non-malignant prostate epithelial cells. That Salinomycin disabled PCSC cancer and function was clear by the discoveries of reduced CD44+ cell fraction and ALDH activity. Also, Salinomycin lessened the expression of MYC, AR and ERG; incited oxidative stress; and, hindered NF-kB action and cell migration[43-45].

Regulation of the cell cycle is frequently adjusted in Prostate Cancer, partially, by the transaction of activation of oncogenic cascades with different hormones, cancer factor, and cytokines. Along these lines, inhibitors of cell cycle regulatory proteins have turned into an area of increased interest for targeting on CSCs. The cyclin-dependent kinase inhibitor VMY-1-103 inhibited at low concentration the Erb-2/Erb-3/heregulin-affected cell multiplication in LNCaP Prostate Cancer cells[46]. It was likewise observed that VMY-1-103 impelled apoptosis through diminished mitochondrial membrane polarity; and incited p53 phosphorylation, caspase-3 activation, and PARP cleavage in Prostate Cancer cells, which do express endogen wild type p53. Anyway, VMY-1-103 failed to induce apoptosis in the p53-null Prostate Cancer cell line PC3. These outcomes, emphatically propose that VMY-1-103 may be a viable therapeutic agents, either alone or in combinations with different medications, in treating Prostate Cancer[47-50].

Adhesion receptors of the integrin family, especially av-integrins, have capacities including bone homing by tumor cells, tumor-induced angiogenesis, and osteoclastic bone resorption. Focusing of integrins by an av-integrin antagonist (GLPG0187) could hinder the de novo formation and movement of bone metastases in Prostate Cancer by antitumor, antiresorptive, and antiangiogenic mechanism[51].

Figure:-2 Macromolecule Combination Therapy



Focusing on the local microenvironment niche and stromal segments of the CSCs would contain two other promising therapeutic methodologies[52]. For example, it is realized that especially the consolidated utilization of antiangiogenic agents with cytotoxic medications represses tumor development and intrusion. Consolidating Docetaxel with the EGFR-targeting agent cetuximab and the antiangiogenic agent sunitinib (SUTENT) inhibit tumor cancer approximately half toward the end of the third week dosing schedule. Focusing on the fibroblast-to-myofibroblast transition with halofuginone (inhibitor of collagen type I) might likewise synergize with low dosages of chemotherapy in accomplishing a significant antitumor impact, maintaining a strategic distance from the need of high-dose chemotherapy and its toxicity without impeding treatment viability. These outcomes all support the thought that focusing on PCSCs, their further differentiated progenies, and microenvironment could be more viable to balance Prostate Cancer transition to intrusive and metastatic stages[53-56].

Closing Remarks

Considering the gigantic advancement made in the previous 10 years, I imagine proceeding with propels over the next decade in area of investigation that will encourage viable methodologies for the anticipation, diagnosis, and treatment of prostate cancer. Among the challenges for future investigations will be to coordinate epidemiological studies with molecular research and clinical analysis to get crucial bits of knowledge into how ecological, dietary, and lifestyle impacts contribute to the development of prostate cancer, and to distinguish the molecular variables that are changed by these impacts and how they can be altered by suitable dietary or chemical interventions. Of vital significance will be the effective diagnosis of men that have prostate cancer, and their stratification into high-risk and low -risk groups for treatment management. In this manner, biomarker revelation will probably represent an impressive accentuation for future investigation, maybe centered on recognizable proof of master regulator genes that can give precise readouts of flagging pathways associated with illness progression.

Also, considering that prostate cancer is decently sluggish, the development of treatment methodologies that postpone its onset or progression is liable to have a critical effect on outcome. At long last, more powerful methods will be necessary for avoiding the transition to deadly forms of prostate tumor, which will oblige a deeper understanding of the mechanism underlying castration resistant prostate cancer and the bone tropism of prostate cancer metastasis. In this way, while our knowledge of the molecular genetics of prostate cancer has enormously extended in the past decade, much work remain to be carried out to enhance the overall rate of prostate tumor survival.

Regardless of all latest developments in cancer determination and treatment, Prostate Cancer still stays one of the main sources of cancer related death in men. In any case, designed new techniques for exact diagnosis will empower researchers to recognize subjects "who will be recurred prior, however will require more broad medications" from those "who will have lifespan less effected from their sickness". Not at all like some other strong tumors, Prostate Cancer one of those tumor types in which constrained treatment alternatives are accessible so far and medication resistance is seen more regularly. That is the reason there is an earnest requirement for alternative and novel treatments.

Conflicts of Interest Statement:

The Authors declare no conflicts of interest.

References:-

(1) Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, Berry PA, Hyde CF, Lewis JL, Stower MJ, et al. 2008. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9: R83. doi:10.1186/gb-2008-9-5-r83.

(2) Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE, Bhowmick NA.2008. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 14: 7790–7797.

(3) Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al. 2008. The miR-15a–miR-16-1 cluster controls prostate cancer by target- ing multiple oncogenic activities. Nat Med 14: 1271–1277.

(4) Bonkhoff H, Berges R. 2010. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70: 100–112. Boormans JL, Hermans KG, van Leenders GJ, Trapman J, Verhagen PC. 2008. An activating mutation in AKT1 in human prostate cancer. Int J Cancer 123: 2725–2726.

(5) Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. 2006. Inflammation and atrophy pre-cede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 8: 708–715.

(6) Shen MM, Abate-Shen C. Molecular genetics of pros- tate cancer: new prospects for old challenges. Genes Dev 2010; 24:1967-2000; PMID:20844012; http:// dx.doi.org/10.1101/gad.1965810

(7) Siegel R, Naishadham D, Jemal A. Cancer sta- tistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/ caac.20138

(8) Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000; 14:2410-34; PMID:11018010;http://dx.doi.org/10.1101/ gad.819500

(9) Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005; 23:8146-51; PMID:16278465; http://dx.doi.org/10.1200/ JCO.2005.02.9751

(10) Li H, Tang DG. Prostate cancer stem cells and their potential roles in metastasis. J Surg Oncol 2011; 103:558-62; PMID:21480250; http://dx.doi. org/10.1002/jso.21806

(11) Feldman BJ, Feldman D. The development of andro- gen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45; PMID:11900250; http://dx.doi. org/10.1038/35094009

(12) Debes JD, Tindall DJ. Mechanisms of androgen-refrac- tory prostate cancer. N Engl J Med 2004; 351:1488-90; PMID:15470210; http://dx.doi.org/10.1056/ NEJMp048178

(13) Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012; 10:556-69; PMID:22560078; http://dx.doi.org/10.1016/j. stem.2012.03.009

(14) Azmi AS, Sarkar FH. Prostate cancer stem cells: molecular characterization for targeted therapy. Asian J Androl 2012; 14:659-60; PMID:22728671; http:// dx.doi.org/10.1038/aja.2012.62

(15) Mulholland DJ. PSA-negative/low prostate cancer cells: the true villains of CRPC? Asian J Androl 2012; 14:663-4; PMID:22820854; http://dx.doi. org/10.1038/aja.2012.69

(16) Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012; 22:373-88; PMID:22975379; http:// dx.doi.org/10.1016/j.ccr.2012.07.016

(17) Shackleton M, Quintana E, Fearon ER, Morrison SJ.Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009; 138:822-9; PMID:19737509; http://dx.doi.org/10.1016/j.cell.2009.08.017

(18) Tang DG. Understanding cancer stem cell hetero- geneity and plasticity. Cell Res 2012; 22:457-72; PMID:22357481; http://dx.doi.org/10.1038/ cr.2012.13

(19) Visvader JE, Lindeman GJ. Cancer stem cells: cur- rent status and evolving complexities. Cell Stem Cell 2012; 10:717-28; PMID:22704512; http://dx.doi. org/10.1016/j.stem.2012.05.007.

(20) Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194:23-8; PMID:959840; http:// dx.doi.org/10.1126/science.959840.

(21) Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11:726-34; PMID:21941284; http://dx.doi.org/10.1038/nrc3130.

(22) Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66:9339-44; PMID:16990346; http://dx.doi.org/10.1158/0008-5472.CAN-06-3126

(23) Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17:313-9; PMID:21386835; http://dx.doi.org/10.1038/nm.2304.

(24) Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21:283-96; PMID:22439924; http:// dx.doi.org/10.1016/j.ccr.2012.03.003

(25) Reya T, Morrison SJ, Clarke MF, Weissman IL.Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11; PMID:11689955; http://dx.doi. org/10.1038/35102167.

(26) Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012;12:133-43; PMID:22237392.

(27) Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012; 12:767-75; PMID:23051844; http://dx.doi. org/10.1038/nrc3368.

(28) Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-8; PMID:7509044; http://dx.doi.org/10.1038/367645a0.

(29) Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; http://dx.doi.org/10.1038/nm0797-730.

(30) Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumori- genic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8; PMID:12629218; http://dx.doi. org/10.1073/pnas.0530291100.

(31) Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140:62-73; PMID:20074520; http://dx.doi.org/10.1016/j.cell.2009.12.007.

(32) Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenic-ity of breast cancer cells. Cell 2007; 131:1109-23; PMID:18083101;http://dx.doi.org/10.1016/j. cell.2007.10.054.

(33) O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour cancer in immunodeficient mice. Nature 2007; 445:106-10; PMID:17122772; http://dx.doi.org/10.1038/nature05372.

(34) Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature2007; 445:111-5; PMID:17122771; http://dx.doi. org/10.1038/nature05384.

(35) Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor cancer and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1:389-402; PMID:18371377; http://dx.doi.org/10.1016/j. stem.2007.08.001.

(36) Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401; PMID:15549107; http://dx.doi.org/10.1038/nature03128.

(37) Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler- Militello D, Misuraca KL, et al. Glioma stem cell prolif- eration and tumor cancer are promoted by nitric oxide synthase-2. Cell 2011; 146:53-66; PMID:21729780; http://dx.doi.org/10.1016/j.cell.2011.06.006.

(38) Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60; PMID:17051156; http:// dx.doi.org/10.1038/nature05236.

(39) Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65:6207-19; PMID:16024622; http://dx.doi.org/10.1158/0008-5472.CAN-05-0592.

(40) Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25:1696-708; PMID:16449977; http://dx.doi.org/10.1038/sj.onc.1209327.

(41) Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007; 67:6796-805; PMID:17638891; http:// dx.doi.org/10.1158/0008-5472.CAN-07-0490.

(42) Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005; 65:6640-50; PMID:16061644; http://dx.doi.org/10.1158/0008-5472.CAN-04-2548

(43) Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-51; PMID:16322242; http://dx.doi.org/10.1158/0008-5472.CAN-05-2018

(44) Collins AT, Habib FK, Maitland NJ,Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001;114: 3865-72.

(45) Burger PE, Xiong X, Coetzee S, Salm SN, Moscatelli D, Goto K,Wilson EL. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high ca- pacity to reconstitute prostatic tissue. Proc Natl Acad Sci U S A 2005;102: 7180-5.

(46) Xin L, Lawson DA,Witte ON. The Sca-1 cell surface marker enriches for a prostate- regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005;102: 6942-7.

(47) Lawson DA, Xin L, Lukacs RU, Cheng D,Witte ON. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A 2007;104: 181-6.

(48) Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL,Nagle RB. Differ- ential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 1994;145: 167-74.

(49) Habermann H, Ray V, Habermann W,Prins GS. Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol2002;167: 655-60.

(50) Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL,Foster BA. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and cancer factors. J Androl 1992;13: 465-75.

(51) Wang XD, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, Aguet M, de Sauvage FJ,Gao WQ. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006;290: 66-80.

(52) Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D,Wilson EL. TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol2005;170: 81-90.

(53) Virchow R. Cellular pathology. Arch Pathol Anat Physiol Klin Med 1855;8: 3-39.

(54) J. Furth KM. The transmission of leukemia in mice with a single cell. Am J CancerRes 1937;31: 276-82.

(55) Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ,Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.

(56) Moltzahn FR, Volkmer JP, Rottke D,Ackermann R. "Cancer stem cells"-lessons fromHercules to fight the Hydra. Urol Oncol 2008;26: 581-9.